Skip to main content

Tenofovir Alafenamide News

FDA Expands Indication for Gilead's Vemlidy (tenofovir alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

March 28, 2024 – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug...

USPSTF Reaffirms Recommendation of PrEP for Those at Increased HIV Risk

TUESDAY, Aug. 22, 2023 – The U.S. Preventive Services Task Force (USPSTF) recommends prescription of preexposure prophylaxis (PrEP) with effective antiretroviral therapy for individuals at increased...

U.S. Food and Drug Administration Approves Vemlidy (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients

Approval Expands on Previous FDA Approval of Vemlidy in Adults Living With This Chronic Liver Disease Efficacy and Safety of Once-Daily Vemlidy Demonstrated in Individuals 12 Years of Age and Older ...

FDA Approves Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for Treatment of HIV-1 Infection

FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir...

FDA Approves Gilead’s Vemlidy (tenofovir alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection

FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy (tenofovir...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Tenofovir Alafenamide patient information at Drugs.com